Press release
Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment
About this update from Insmed Incorporated
[{"type":"text","content":"—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses—\n—Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE® (amikacin liposome inhalation suspension) in Frontline Patients with MAC Lung Disease—Less than Half that of Pivotal Trial in Refractory Patients—\n—Blended, Blinded Event Rate Ranging from 1.12 to 1.15 Events Per Patient Per Year Reported in Phase 3 ASPEN Trial of Brensocatib in Patients with Bronchiectasis, in Line with Expectations—\n—Company Expects to Report 30% Global Revenue Growth for ARIKAYCE in 2022 Compared with 2021—\n—2023 Global ARIKAYCE Revenues Expected to be Between $285 Million and $300 Million—\nBRIDGEWATER, N.J., Jan. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlined its near-term strategic priorities. These updates will be discussed as part of the Company's presentation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET).\n\"With a strong commercial engine, meaningful cash on hand, and a maturing pipeline with multiple near-term catalysts, Insmed is well-positioned to become one of the next great multiproduct biotechnology companies,\" said Will Lewis, Chair and Chief Executive Officer of Insmed. \"The next 18 months will be the most critical period in our history as we share clinical data from across our pipeline and set the stage for sustainable growth that will enable us to go from serving tens of thousands of patients with serious and rare diseases to potentially more than 1 million. Importantly, we are very encouraged by the data we reported today from our Phase 2 PK/PD study of brensocatib in patients with cystic fibrosis, which show clear dose-dependent inhibition of neutrophil serine proteases across all doses and support the mechanism of action of this highly innovative potential therapy.\"\nStrategic Priorities:Insmed is focused on the following near-term strategic priorities:\nControl expenses by leveraging our reliable revenue stream while carefully deploying capital from significant cash on hand to advance ou...